YM BioSciences To Pursue Nimotuzumab Pediatric Brain Cancer Study
This article was originally published in The Pink Sheet Daily
Executive Summary
Enrollment in a European Phase III trial for the mAb as a first-line treatment for pediatric diffuse intrinsic pontine glioma has initiated.
You may also be interested in...
YM BioSciences Terminates Phase III Breast Cancer Trial
Future of separate program involving tesmilifene in combination with Sanofi-Aventis’ Taxotere remains uncertain, company says.
Solvay's Androgel REMS Proposal May Need More Restrictions - Cmte.
Solvay may need a more restrictive Risk Evaluation and Mitigation Strategy for AndroGel 1% to adequately warn against the danger of secondary transfer of the testosterone gel, according to some members of FDA's Pediatric Advisory Committee
FDA Complete Response Slows Down, But Won't Stop, Lundbeck's Serdolect
Agency comes to same conclusion as advisory committee: the risky schizophrenia drug could get approved if an appropriate patient group is identified.